Sanjeet Dadwal, MD
Infectious Disease · Duarte, CANPI 1669589537
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 46.0% of the total. Reporting peaked in 2022 at $60,165 and has fallen 86.0% since, to $8,436 in 2025. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $1019.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$82K
- Merck$70K
- Astellas Pharma US Inc$14K
- Shionogi Inc$8K
- Janssen Global Services, LLC$2K
- Melinta Therapeutics, LLC$425
- plus $342 from 3 others
Across 187 payments — averaging $3834.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$501K
- Pfizer$162K
- Gilead$20K
- Janssen Research & Development, LLC$17K
- Shire North American Group Inc$13K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Consulting fees$40,25423%
- Speaking & faculty fees$89,41150%
- Travel & lodging$44,14925%
- Food & beverage$3,6452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 68 | $81,580 |
| Merck | 62 | $70,408 |
| Astellas Pharma US Inc | 15 | $13,898 |
| Shionogi Inc | 16 | $8,326 |
| Janssen Global Services, LLC | 1 | $2,480 |
| Melinta Therapeutics, LLC | 6 | $425 |
| AstraZeneca | 4 | $140 |
| Incyte Corporation | 1 | $128 |
| Ferring Pharmaceuticals Inc. | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$177,459 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Duarte
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
- Shawn HasslerSan Francisco$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.